EIF2A and atherosclerosis: This suggests that the exacerbation of the UPR, which is dependent on EIF2A, can be thought as a relevant strategy to potentiate the effect of FK866 in conditions in which activation of the EIF2A-dependent UPR is desirable, i.e., diabetes, atherosclerosis, or neurodegenerative disorders [51].